GlassScriptPhysician profile
Michelle Selvaggi
NPI 1275918385
$10,240.36
in general payments reported to CMS, 2019-2025
34 companies · $2,658 in 2025
The $2,658 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,070 · 2022: $1,345 · 2023: $1,428 · 2024: $2,740 · 2025: $2,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,735 · Education: $91.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,734.92 |
| Education | $91.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,803.07 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,076.59 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $914.90 | 2021-2025 | |
| Janssen Biotech, INC. | $765.19 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $613.48 | 2021-2025 | |
| Incyte Corporation | $530.79 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $485.33 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $460.97 | 2021-2025 | Bimzelx, Cimzia |
| Revance Therapeutics, INC. | $410.69 | 2024 | Daxxify, Daxi |
| Leo Pharma INC. | $407.63 | 2021-2025 | Adbry |
| Pfizer INC. | $371.08 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $242.65 | 2023-2024 | Sotyktu |
| Amgen INC. | $237.03 | 2021-2025 | Otezla, Otezla |
| Merz North America, INC. | $231.07 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.62 | 2022-2025 | Spevigo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $160.04 | 2021-2025 | Seysara, Klisyri |
| Janssen Scientific Affairs, LLC | $149.17 | 2025 | Tremfya |
| Galderma Laboratories, L.P. | $147.50 | 2025 | Nemluvio |
| Lilly USA, LLC | $138.08 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $137.43 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.80 | 2021-2025 | Siliq |
| Dermavant Sciences, INC. | $91.65 | 2022-2024 | Vtama |
| Epi Health, LLC | $80.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Biofrontera INC. | $74.18 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $60.53 | 2025 | Vtama |
| Journey Medical Corporation | $60.03 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $49.24 | 2021-2025 | |
| Krystal Biotech INC | $41.35 | 2024 | Vyjuvek |
| Sebela Pharmaceuticals INC. | $38.46 | 2021-2022 | |
| Allergan, INC. | $32.05 | 2021 | |
| Verrica Pharmaceuticals INC. | $26.10 | 2024 | Ycanth |
| Paratek Pharmaceuticals, INC. | $17.38 | 2023 | Nuzyra |
| Lnhc, INC | $16.00 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Selvaggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.